Anne G W E Wintjens, Hong Liu, Peter-Paul K H Fransen, Kaatje Lenaerts, Geert C van Almen, Marion J Gijbels, M'hamed Hadfoune, Bas T C Boonen, Natasja G Lieuwes, Rianne Biemans, Ludwig J Dubois, Patricia Y W Dankers, Ignace H J T de Hingh, Nicole D Bouvy
Patients with peritoneal metastases (PM) of colorectal cancer have a very poor outcome. Intraperitoneal delivery of chemotherapy is the preferred route for PM treatment. The main limitation of the treatment options is the short residence time of the cytostatic, with subsequent short exposure of the cancer cells. To address this, a supramolecular hydrogel has been developed that allows both local and slow release of its encapsulated drug, mitomycin C (MMC) or cholesterol-conjugated MMC (cMMC), respectively. This experimental study investigates if drug delivery using this hydrogel improves the therapeutic efficacy against PM...
May 22, 2023: Clinical & Experimental Metastasis